Cargando…
A phase 3 double-blind randomized (CONSORT-compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension
BACKGROUND: Azilsartan medoxomil (AZL-M), an angiotensin II receptor blocker, has a well-characterized efficacy and safety profile in patients with hypertension. AZL-M is approved for use in over 40 countries globally; however, it is not yet approved in China. Therefore, a phase 3 registration study...
Autores principales: | Wu, Jiahui, Du, Xin, Lv, Qiang, Li, Zhanquan, Zheng, Zeqi, Xia, Yong, Tang, Chengchun, Yao, Zhuhua, Zhang, Jun, Long, Mingzhi, Hisada, Michie, Wu, Jingtao, Zhou, Wei, Ma, Changsheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505320/ https://www.ncbi.nlm.nih.gov/pubmed/32769878 http://dx.doi.org/10.1097/MD.0000000000021465 |
Ejemplares similares
-
A phase 3 double-blind randomized (CONSORT-compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension: Erratum
Publicado: (2020) -
Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension
por: Juhasz, Attila, et al.
Publicado: (2018) -
Efficacy and safety of different doses of azilsartan medoxomil in patients with hypertension: A protocol of a network meta-analysis
por: Zhang, Yan, et al.
Publicado: (2019) -
Use of azilsartan medoxomil in the primary-care setting in Germany: A real-world evidence study
por: Ehlken, Birgit, et al.
Publicado: (2019) -
Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes
por: White, William B., et al.
Publicado: (2016)